WO1991015572A1 - Live vaccines - Google Patents
Live vaccines Download PDFInfo
- Publication number
- WO1991015572A1 WO1991015572A1 PCT/GB1991/000484 GB9100484W WO9115572A1 WO 1991015572 A1 WO1991015572 A1 WO 1991015572A1 GB 9100484 W GB9100484 W GB 9100484W WO 9115572 A1 WO9115572 A1 WO 9115572A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microorganism
- protein
- attenuated
- dna sequence
- mutation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
Definitions
- the present invention relates to attenuated microorganisms, to methods for their production, to their use in the immunoprophylaxis of an animal or a human, and to vaccines containing them.
- the principle behind vaccination or immunoprophylaxis is to induce an immune response in an animal to a pathogenic organism by innoculation with an attenuated strain of the organism thus providing protection against subsequent challenge.
- Bacon et al (Br.J.Exp.Path. 31. 714-724) demonstrated that certain auxotrophic mutants of S.tvphi were attenuated in mice when compared to the parental strain. Certain of these auxotrophic mutants have been proposed as being suitable candidates for the basis of a whole cell vaccine. (See for example Hosieth and Stocker, Nature. 1981 241, 238-239, and European patent publication 322,237).
- loci In addition to mutations in an essential auxotrophic pathway, other loci have been identified where mutations result in attenuation of microorganisms. Examples of such loci include regulons that exert pleiotrophic effects, e.g., the cva/crp system (Roy Curtiss III et al. Vaccine j5, 155-160, 1988) and the ompR envZ system (Dorman et al. T-nf ->c.r., ⁇ I ⁇ I ⁇ TI 57. 2136-2140, 1989) and the phoP system (Fields ej ______ Science 243. 1059-1062, 1989).
- the cva/crp system Roy Curtiss III et al. Vaccine j5, 155-160, 1988
- ompR envZ system Dorman et al. T-nf ->c.r., ⁇ I ⁇ I ⁇ TI 57. 2136-2140,
- Hsp90, Hsp70 and Hsp60 are heat shock proteins found in all prokaryotes and eukaryotes. Amino acid sequence comparison between Hsp90 from E.coli and that from man shows that approximately half the amino acid residues are identical.
- Other members of the stress protein family are GrpE, GroEL, DnaK, GroES, Lon and DnaJ.
- Escherichia coli and Salmonella tvphimurium Cellular and Molecular
- HtrA heat shock protein in E.coli
- E 24 promoter known to be recognised by ⁇ ( ⁇ ) factor. This similarity suggests that the htrA promoter may also be recognised by the RNA
- the htrA gene has been identified as degP by Strauch, K.L. and Beckwith, J. 1988 (Proc. atl.Acad.Sci. USA 8j_, 1576-1580) who were examining E.coli mutants with decreased protease activity, degP mutants were isolated by TnphoA mutagenesis (Manoil, C. & Beckwith, J. 1985, Proc.Natl.Acad.Sci. USA 82., 8129-8133) and were recognised by the increased stability of a hybrid Tsr-phoA (Tsr-AP2) recombinant protein in a degP background (Strauch, K.L. and Beckwith, J. 1988. Proc.Natl. Acad.Sci. USA £5. 1576-1680).
- the genes identified as degP and htrA appear to be identical and encode a protein that is a member of the 'stress-response' family.
- the present invention provides an attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA of the microorganism which encodes, or which regulates the expression of DNA encoding, a protein that is produced in response to environmental stress, the microorganisir. optionally being capable of expressing DNA encoding a heterologous antigen.
- the microorganisms for use with the present invention are preferably bacteria especially Gram-negative bacteria which invade and grow within eucaryotic cells and colonise the muscosal surface.
- bacteria especially Gram-negative bacteria which invade and grow within eucaryotic cells and colonise the muscosal surface. Examples of these include members of the genera Salmonella. Bordetella. Vibrio. Haemophilus and Escherichia.
- S.tvphi the cause of human typhoid
- S.tvphimurium the cause of salmonellosis in several animal species
- S.enteritidis a cause of food poisoning in humans
- S.choleraesuis the cause of salmonellosis in pigs
- Bordetella pertussis the cause of whooping cough
- Neisseria ponorrhoeae - the cause of gonorrhoea the cause of gonorrhoea.
- the mutation of the DNA is a non-reverting mutation, namely one which cannot be repaired in a single step.
- Genetic mutations of this sort include deletion, inversion, insertion or substitution mutations.
- Deletion mutations can be generated using transposons. These are DNA sequences comprising from between 750 to thousands of base pairs which can integrate into the host's chromosomal DNA. The continuity of the DNA sequence of interest is thus disrupted with the loss of gene function.
- Transposons can be deleted from the host chromosomal DNA; most frequently excision is imprecise leading to a non-reverting mutation.
- Substitution or insertion mutations can arise by use of an inactivated DNA sequence carried on a vector which recombines with or crosses-over with the DNA sequence of interest in the host's chromosomal DNA with the consequent loss of gene function.
- proteins that are produced in response to environmental stress include heat shock proteins (which are produced in response to a temperature increase above 42 C) ; nutrient deprivation proteins (which are produced in response to levels of essential nutrients such as phosphates or nitrogen which are below that which the microorganism requires to survive) ; toxic stress proteins (which are produced in response to toxic compounds such as dyes, acids or possibly plant exudates) ; or metabolic disruption proteins (which are produced in response to fluctuations in for example ion levels affecting the microorganisms ability to osmoregulate, or vitamin or co-factor levels such as to disrupt metabolism) .
- heat shock proteins which are produced in response to a temperature increase above 42 C
- nutrient deprivation proteins which are produced in response to levels of essential nutrients such as phosphates or nitrogen which are below that which the microorganism requires to survive
- toxic stress proteins which are produced in response to toxic compounds such as dyes, acids or possibly plant exudates
- metabolic disruption proteins which are produced in response to fluctuations in for example i
- a heat shock protein is the one encoded by the htrA gene as set out in Fig. 1.
- SEQ ID No: 1 also characterised as degP
- Other proteins are encoded by genes known to be involved in the stress response such as prpE. groEL. (moPA) . dnaK. groES. Ion and dnaJ .
- proteins There are many other proteins encoded by genes which are known to be induced in response to environmental stress (Ronson et al. Cell 49. 579-581) . Amongst these the following can be mentioned: the ntrB/ntrC system of E.coli.
- Rhizobium An analogous system in Rhizobium is dctB/dctD. which is responsive to 4C-discarboxylic acids (Ronson et Si. , J.Bacteriol. 169, 2424 and Cell 49, 579-581, 1987).
- a virulence system of this type has been described in Agrobacterium. This is the virA/virG system, which is induced in response to plant exudates (le
- the attenuated microorganism of the present invention does not revert back to the virulent state.
- the probability of this happening with a mutation in a single DNA sequence is considered to be small.
- the risk of reversion occurring with a microorganism attenuated by the presence of mutations in each of two discrete DNA sequences is considered to be insignificant. It is preferred therefore that the attenuation of the microorganism of the present invention is brought about by the presence of a mutation in the DNA sequence which encodes, or which regulates the expression of DNA encoding, a protein that is produced in response to environmental stress and by the presence of a mutation in a second DNA sequence.
- the second DNA sequence preferably encodes an enzyme involved in an essential auxotrophic pathway or is a sequence whose product controls the regulation of osmotically responsive genes, i.e. ompR. (Infect and Immun 1989 2136-2140).
- the mutation is in a DNA sequence involved in the aromatic amino acid biosynthetic pathway, more particularly the DNA sequences encoding aroA. aroC or aroD. (EP Publication Number 322237) .
- the attenuated microorganisms of the present invention are constructed by the introduction of a mutation into the DNA sequence by methods known to those skilled in the art (Maniatis, Molecular Cloning and Laboratory Manual, 1982).
- Non-reverting mutations can be generated by introducing a hybrid transposon TnphoA into, for example, S.tvphimurium strains.
- TnphoA can generate enzymatically active protein fusions of alkaline phosphatase to periplasmic or membrane proteins.
- the TnphoA transposon carries a gene encoding kanamycin resistance. Transductants are selected that are kanamycin resistant by growing colonies on an appropriate selection medium.
- Alternative methods include cloning the DNA sequence into a vector, eg. a plasmid or cosmid, inserting a selectable marker gene into the cloned DNA sequence, resulting in its inactivation.
- a plasmid carrying the inactivated DNA sequence and a different selectable marker can be introduced into the organism by known techniques (Maniatis, Molecular Cloning and Laboratory Manual, 1982). It is then possible by suitable selection to identify a mutant wherein the inactivated DNA sequence has recombined into the chromosome of the microorganism and the wild-type DNA sequence has been rendered non-functional in a process known as allelic exchange.
- the vector used is preferably unstable in the microorganism and will be spontaneously lost.
- the mutated DNA sequence on the plasmid and the wild-type DNA sequence may be exchanged by a genetic cross-over event. Additional methods eliminate the introduction of foreign DNA into vaccine strains at the site of mutations.
- the invention therefore provides a process for the production of an attenuated microorganism according to the invention which comprises introduction of a mutation in the DNA sequence of the microorganism which encodes, or which regulates expression of a DNA sequence encoding, a protein that is produced in response to environmental stress, by either
- transposon mutagenesis a) transposon mutagenesis; or b) transforming the microorganism with a vector incorporating a
- the attenuated microorganism of the present invention is optionally capable of expressing a heterologous antigen. This expression is likely to be more favourable in htrA mutants because of the increased stability of recombinant antigens associated with the dep? phenotype..
- antigens may be viral, bacterial, protozoal or of higher parasitic microorganisms.
- microorganisms may then form the basis of a bi- or multi-valent vaccine.
- useful antigens include E.coli heat labile toxin B subunit (LT-B) , E.coli K88 antigens, FMDV (Foot and Mouth) peptides , Influenza viral proteins, P.69 protein from B. ertussis.
- Other antigens which could be usefully expressed would be those from Chlamvdia. flukes, mycoplasma, roundworms, tapeworms, rabies virus and rotavirus.
- a microorganism capable of expressing DNA encoding a heterologous antigen may be produced by transformation of the microorganism with an expression cassette.
- Expression cassettes will include DNA sequences, in addition to that coding for the heterologous antigen, which will encode transcriptional and translational initiation and termination sequences.
- the expression cassette may also include regulatory sequences. Such expression cassettes are well known in the art and it is well within the ability of the skilled man to construct them.
- the expression cassette may form part of a vector construct or a naturally occurring plasmid.
- An example of a genetically engineered attenuated Salmonella which is capable of expressing a heterologous antigen is described in EP publication 127,153.
- the expression cassette may also be engineered to allow the incorporation of the heterologous gene into the chromosome of the microorganism.
- a further bivalent vaccine comprising an attenuated Salmonella tvphi. capable of expressing the E.coli heat-labile enterotoxin subunit B is disclosed by Clements et al (Infection ad Immunity, 46., No.2. 1984, 564-569).
- Ty21a an attenuated S.tvphi strain, has been used to express other antigens such as the Shipella sonnei form I antigen (Formal et al.. Infection and Immunity, 34, 746-750, 1981).
- a vaccine which comprises an effective amount of an attenuated microorganism, preferably a bacterium, as herein described and a pharmaceutically acceptable carrier.
- the vaccine is advantageously presented in a lyophilised form, for example in a capsular form, for oral administration to a patient.
- a lyophilised form for example in a capsular form, for oral administration to a patient.
- Such capsules may be provided with an enteric coating comprising for example Eudragate "S” Eudragate “L” Cellulose acetate, cellulose pthalate or hydroxy propylmethyl cellulose.
- the lyophilised material may be reconstituted prior to administration, eg. as a suspension. Reconstitution is advantageously effected in a buffer at a suitable pH to ensure the viability of the organisms.
- a sodium bicarbonate preparation is advantageously administered before each administration of the vaccine.
- the vaccine may be prepared for parenteral administration, intranasal administration or intramammary.
- the present invention also provides a method of prophylactic treatment of a host (particularly a human host) with an infection caused by a microorganism which comprises administering to said host an effective dose of a vaccine according to the invention.
- the dosage employed in such a method of treatment will be dependent on various clinical factors, including the size and weight of the host, the type of vaccine formulated. However, for attenuated S.tvphi a dosage comprising the administration of 10 to 10 S.tvphi organisms per dose is generally convenient for a 70kg adult human host.
- Figure 1 DNA sequence of the htrA gene and the amino acid sequence of the protein it encodes.
- FIG. 3 In vivo kinetics of S.tvphimurium strains harbouring a mutation in htrA (BRD726) and htrA aro mutations (BRD807).
- TnphoA mutagenesis was used in the mouse virulent Salmonella tvphimurium strain C5 (Miller et al. 1989, Infect.Immunol, 57. 2758-2763). Mutants were selected likely to harbour lesions in genes that have a signal peptide sequence, i.e. proteins likely to be targeted through a bacterial membrane. Isolation of the DNA flanking the TnphoA insertion identifies the gene that has been insertionally activated. This gene was isolated and its DNA sequence was determined by standard methods (see Figure 1. SEQ ID No: 1) (Maniatis et al.. 1982, In Molecular Cloning: A laboratory manual. Cold Spring Harbour Laboratory, Cold Spring Harbour, N.Y. ; Sanger _____________• , 1977,
- E.Coli mutants harbouring lesions in the htrA gene are unable to grow at temperatures above 42 C.
- the S.tvphimurium htrA mutant, 046 was tested for growth at elevated temperatures and was found to grow as well as the present strain C5.
- the mutant 046 showed decreased resistance as compared with the parent C5 strain clearly indicating that the gene is responsible (at least in part) for this aspect of the stress response (see Fig. 2) .
- the attenuated strains were constructed using TnphoA transposon mutagenesis as described previously (Miller et al.. 1989, Infect. Immun. 57, 2758-2763).
- the mutant strain 046 had a Log. n LD,_ n of greater than 9 cells as compared to the parental strain, C5, which has a Lo - 0 D 50 of 6.38 cells. (All LD- Q were calculated after 28 days). Thus 046 is highly attenuated. After i.v. administration 046 had an i.v. Log- n LD,_ of 5.13 cells compared to less than 10 cells for C5 and we again conclude that 046 is highly attenuated compared to C5.
- mice were immunised with 046 and challenged 28 days later with the virulent parental strain C5. Mice vaccinated with using 10 cells of 046 showed excellent protection against challenge with C5. eleven weeks after vaccination.
- the Log.-. LD-._ in immunised animals was 9.64 cells compared with 6.6 cells for unimmunised controls. Thus, mice vaccinated orally with a single dose of 046 were well protected against virulent C5 challenge.
- Sequence data facilitated the identification of suitable restriction endonuclease sites that could be used to introduce a deletion into the htrA gene.
- a 1.2Kb deletion was introduced by digesting with EcoRV and religating.
- a drug resistant marker was also introduced into the gene (Kanamycin cassette, Pharmacia) by standard techniques to enable selection for the presence of the deleted gene.
- the plasmid harbouring the deleted htrA gene was introduced into a polA strain S.tvphimurium (BRD207) in which the plasmid cannot replicate.
- kanamycin resistance can be maintained in the host is if there has been a recombination event between the S.tvphimurium sequences on the vector and the homologous regions on the chromosome. Loss of ampicillin resistance while maintaining kanamycin resistance indicates a second homologous recombination event resulting in the replacement of the intact htrA gene with the deleted one. Colonies resistant to kanamycin were isolated and checked for ampicillin resistance. One colony that was kanamycin resistant and ampicillin sensitive was selected for further study and was designated BRD698 (deposited at PHLS, NCTC, 61 Colindale Avenue, London NW9 5HT under Accession No on in accordance with the terms of the
- a P22 lysate was prepared on this strain by standard techniques (Dougan et aJL, J.Infect.Dis. 1__8.. 1329-1335, 1988) and used to infect SL1344. Kanamycin resistant colonies were isolated and checked for the presence of the deletion by Southern hybridisation.
- One strain, designated BRD726 (deposited at PHLS under Accession No on in accordance with the terms of the Budapest Treaty) was selected for further study.
- the P22 lysate prepared on BRD698 was used to introduce the htrA deletion into an S.tvphimurium SL1344 strain already harbouring a deletion in aroA.
- the method for introducing an aroA deletion has already been described by Dougan e_t al, J.Infect.Dis. 158. 1329-1335, 1988.
- One strain that was found to have deletions in both aroA and htrA was selected for further study and was designated BRD807,
- BRD726 and BRD807 had Log. Q ID s of >10.0 cells compared to the virulent parent strain which has a Log.,. LD_. n of 6.8 cells*. Both strains were therefore highly attenuated compared to the virulent parent strain SL1344.
- mice were orally immunised with approximately 10 cells of BRD726 and BRD807 as previously described (Dougan et al, J.Infect.Dis. 158. 1329-1335, 1988) and challenged 4 and 10 weeks later with the virulent parent strain SL1344.
- LD_*n s were calculated by the method of Reed and Muench (Am.J.Hyg. 22., 493-497, 1934). All determinations were carried out at least twice. Mice vaccinated with BRD726 and BRD807 showed excellent protection against challenge with SL1344 at weeks, the lo -i f , LD. S being >10.0 and 9.7 cells respectively. This compares with log 6.1 cells for unimmunised controls.
- mice immunised with BRD726 had excellent long term immunity to virulent SL1344 challenge. This compares favourably with protection elicited by double aro mutants of SL1344 (Dougan et al, J.Infect.Dis. 158. 1329-1335, 1988).
- the long term protection afforded by vaccination with BRD807 is 46-fold better than unimmunised controls.
- both BRD726 and BRD807 make good vaccine strains for BALB/c mice.
- BRD726 and BRD807 The ability of BRD726 and BRD807 to grow in vivo after intravenous administration was assessed. Mice were infected with approximately 10 organisms. Numbers of bacteria in livers and spleens were enumerated at different times during the infection up to 21 days. The results obtained are shown in Fig3. Neither BRD726 or BRD807 underwent an initial period of replication in murine tissues. The strains are cleared slowly from the organs and by day 21 BRD807 has almost cleared from the murine tissues while BRD726 is still persisting at low levels.
- Example 10 Example 10
- An attenuated microorganism of the present invention is preferably presented in an oral tablet form.
- Microcrystalline Cellulose 35.0 (Avicel pH102)
- a carrier containing 5% sucrose, 1% sodium glutamate and 1% bacto casitone in an aqueous solvent is prepared. The organisms are suspended in this carrier and then subjected to freeze-drying.
- the freeze-dried material is blended with Aerosil 200 and the blended mixture is sifted through a screen.
- the sifted powder is mixed with Dipac, Kolidan CL, Aricel pH102 and Magnesium Stearate in a blender. This blend is compressed into tablets for subsequent enteric coatings.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002079463A CA2079463C (en) | 1990-03-30 | 1991-03-28 | Live vaccines |
AU75417/91A AU659995C (en) | 1990-03-30 | 1991-03-28 | Live vaccines |
EP91906493A EP0524205B1 (en) | 1990-03-30 | 1991-03-28 | Live vaccines |
DE69127440T DE69127440T2 (en) | 1990-03-30 | 1991-03-28 | LIVING VACCINE |
JP3506347A JP3054440B2 (en) | 1990-03-30 | 1991-03-28 | Live vaccine |
US08/350,741 US5804194A (en) | 1990-03-30 | 1994-12-07 | Vaccines containing a salmonella bacteria attenuated by mutation of the htra gene |
GR970402896T GR3025258T3 (en) | 1990-03-30 | 1997-11-05 | Live vaccines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909007194A GB9007194D0 (en) | 1990-03-30 | 1990-03-30 | Live vaccines |
GB9007194.5 | 1990-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991015572A1 true WO1991015572A1 (en) | 1991-10-17 |
Family
ID=10673583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1991/000484 WO1991015572A1 (en) | 1990-03-30 | 1991-03-28 | Live vaccines |
Country Status (19)
Country | Link |
---|---|
US (2) | US5804194A (en) |
EP (1) | EP0524205B1 (en) |
JP (1) | JP3054440B2 (en) |
KR (1) | KR100202771B1 (en) |
AT (1) | ATE157397T1 (en) |
CA (1) | CA2079463C (en) |
DE (1) | DE69127440T2 (en) |
DK (1) | DK0524205T3 (en) |
ES (1) | ES2106776T3 (en) |
GB (1) | GB9007194D0 (en) |
GR (1) | GR3025258T3 (en) |
HU (1) | HU217776B (en) |
IE (1) | IE911037A1 (en) |
IL (1) | IL97720A (en) |
MY (1) | MY130001A (en) |
NZ (1) | NZ237616A (en) |
TW (1) | TW205567B (en) |
WO (1) | WO1991015572A1 (en) |
ZA (1) | ZA912397B (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995020665A1 (en) * | 1994-01-31 | 1995-08-03 | Medeva Holdings B.V. | Expression of heterologous proteins in attenuated bacteria using the htra-promoters |
US5547664A (en) * | 1991-03-05 | 1996-08-20 | Burroughs Wellcome Co. | Expression of recombinant proteins in attenuated bacteria |
AU675940B2 (en) * | 1992-03-02 | 1997-02-27 | Board Of Trustees Of The Leland Stanford Junior University | Microorganisms having attenuated invasiveness |
US5662908A (en) * | 1985-07-31 | 1997-09-02 | The Board Of Trustees Of The Leland Stanford Jr. University | Invasive microorganisms |
US5747309A (en) * | 1992-09-04 | 1998-05-05 | University Of Saskatchewan | Bacterial vaccines using vaccine strains of pathogenic bacteria |
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5830464A (en) * | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US5837251A (en) * | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5948646A (en) * | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
WO1999049026A1 (en) * | 1998-03-25 | 1999-09-30 | Peptide Therapeutics Limited | Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines |
US5961979A (en) * | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US5985270A (en) * | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US6017540A (en) * | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
FR2787810A1 (en) * | 1998-12-24 | 2000-06-30 | Agronomique Inst Nat Rech | GRAM POSITIVE BACTERIA WITHOUT PROTEASIC ACTIVITY HTRA, AND USES THEREOF |
US6335183B1 (en) | 1988-06-15 | 2002-01-01 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US6413830B1 (en) | 1996-03-01 | 2002-07-02 | Sven E. Wahlstrom | Dynamic random access memory |
WO2002097081A2 (en) * | 2001-05-30 | 2002-12-05 | Brane Tech S.R.L. | Method to generate non virulent microorganisms from pathogenic ones trough permanent genetic modification of their biological membrane for vaccine production |
US6495347B1 (en) | 1999-07-08 | 2002-12-17 | Stressgen Biotechnologies Corporation | Induction of a Th1-like response in vitro |
US6497880B1 (en) | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
US6524825B1 (en) | 1997-08-05 | 2003-02-25 | Stressgen Biotechnologies, Inc. | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
US6797491B2 (en) | 2000-06-26 | 2004-09-28 | Stressgen Biotechnologies Corporation | Human papilloma virus treatment |
US6875435B2 (en) | 2000-01-14 | 2005-04-05 | Whitehead Institute For Biomedical Research | In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
US6921534B2 (en) | 2001-02-05 | 2005-07-26 | Stressgen Biotechnologies Corporation | Hepatitis B virus treatment |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
US7449557B2 (en) | 2000-06-02 | 2008-11-11 | University Of Connecticut Health Center | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
US7666581B2 (en) | 2001-08-20 | 2010-02-23 | University Of Connecticut Health Center | Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease |
WO2013011509A1 (en) * | 2011-07-21 | 2013-01-24 | State Of Israel, Represented By Prime Minister's Office Institute For Biological Research | BACILLUS ANTHRACIS HtrA-DEFECTIVE-DERIVED VACCINES |
US8475785B2 (en) | 2008-03-03 | 2013-07-02 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
US8685384B2 (en) | 1998-02-20 | 2014-04-01 | University Of Miami | Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex |
US8968720B2 (en) | 2008-03-20 | 2015-03-03 | University Of Miami | Heat shock protein GP96 vaccination and methods of using same |
US10046047B2 (en) | 2015-02-06 | 2018-08-14 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6905691B1 (en) | 1997-12-11 | 2005-06-14 | Celltech Pharma Europe Limited | Vaccines containing attenuated bacteria |
CU22661A1 (en) * | 1997-12-30 | 2001-04-27 | Cnic Ct Nac Investigaciones | NEW VACCINE CANDIDATES OF VIBRIO CHOLERAE AND METHOD OF OBTAINING |
US6413768B1 (en) | 1998-12-02 | 2002-07-02 | University Of Maryland | Expression plasmids |
US8076130B2 (en) | 1998-12-02 | 2011-12-13 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
CZ20011538A3 (en) | 1998-12-02 | 2001-11-14 | University Of Maryland, Baltimore | Independently functioning expression cassette, apmlifiable plasmid replicon, bacterial cell, vaccination vector, conditioned unstable plasmid, method of inducing immune response, DNA and expression plasmid |
US6872547B1 (en) | 2000-10-11 | 2005-03-29 | Washington University | Functional balanced-lethal host-vector systems |
GB0121998D0 (en) | 2001-09-11 | 2001-10-31 | Acambis Res Ltd | Attenuated bacteria useful in vaccines |
US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
UA100370C2 (en) | 2006-12-11 | 2012-12-25 | Мериал Лимитед | METHOD OF VACCINATION OF BIRDS AGAINST SALMONELL |
BR112016023915B1 (en) | 2014-04-15 | 2024-03-12 | Griffith University | M PROTEIN FRAGMENT USES AND COMPOSITION |
CA3162559A1 (en) | 2019-11-25 | 2021-06-03 | Griffith University | Immunogenic protein against gonococcal infection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988005821A1 (en) * | 1987-01-30 | 1988-08-11 | President And Fellows Of Harvard College | Periplasmic protease mutants of escherichia coli |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4337314A (en) * | 1979-05-23 | 1982-06-29 | Research Corporation | Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype |
US4735801A (en) * | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
GB8314645D0 (en) * | 1983-05-26 | 1983-06-29 | Wellcome Found | Bivalent vaccines |
US4895717A (en) * | 1987-07-10 | 1990-01-23 | The United States Of America As Represented By The Secretary Of Agriculture | Revertant serotype 1 Marek's disease vaccine |
GB8730037D0 (en) * | 1987-12-23 | 1988-02-03 | Wellcome Found | Vaccines |
US5114844A (en) * | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
GB8912330D0 (en) * | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
-
1990
- 1990-03-30 GB GB909007194A patent/GB9007194D0/en active Pending
-
1991
- 1991-03-28 KR KR1019920702407A patent/KR100202771B1/en not_active IP Right Cessation
- 1991-03-28 NZ NZ237616A patent/NZ237616A/en unknown
- 1991-03-28 MY MYPI91000506A patent/MY130001A/en unknown
- 1991-03-28 ZA ZA912397A patent/ZA912397B/en unknown
- 1991-03-28 DK DK91906493.1T patent/DK0524205T3/en active
- 1991-03-28 ES ES91906493T patent/ES2106776T3/en not_active Expired - Lifetime
- 1991-03-28 TW TW080102452A patent/TW205567B/zh active
- 1991-03-28 IL IL9772091A patent/IL97720A/en not_active IP Right Cessation
- 1991-03-28 DE DE69127440T patent/DE69127440T2/en not_active Expired - Lifetime
- 1991-03-28 HU HU9203098A patent/HU217776B/en unknown
- 1991-03-28 IE IE103791A patent/IE911037A1/en not_active IP Right Cessation
- 1991-03-28 AT AT91906493T patent/ATE157397T1/en not_active IP Right Cessation
- 1991-03-28 EP EP91906493A patent/EP0524205B1/en not_active Expired - Lifetime
- 1991-03-28 WO PCT/GB1991/000484 patent/WO1991015572A1/en active IP Right Grant
- 1991-03-28 CA CA002079463A patent/CA2079463C/en not_active Expired - Lifetime
- 1991-03-28 JP JP3506347A patent/JP3054440B2/en not_active Expired - Lifetime
-
1994
- 1994-12-07 US US08/350,741 patent/US5804194A/en not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/463,875 patent/US5980907A/en not_active Expired - Fee Related
-
1997
- 1997-11-05 GR GR970402896T patent/GR3025258T3/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988005821A1 (en) * | 1987-01-30 | 1988-08-11 | President And Fellows Of Harvard College | Periplasmic protease mutants of escherichia coli |
Non-Patent Citations (9)
Title |
---|
Biological Abstracts, volume 91, K. Johnson et al.: "The role of a stress-response protein in Salmonella typhimurium virulence" * |
Genes and Development, volume 2, 1988, N. Kusukawa et al.: "Heat shock protein GroE of Escherichia coli: key protective roles ageinst thermal stress", pages 874-882 see page 875, column 1 * |
Infection and Immunity, volume 57, no. 9, September 1989, American Society for Microbiology, (US), I. Miller et al.: "Isolation of orally attenuated Salmonella typhimuriaum following TnphoA mutagenesis", pages 2758-2763 * |
Journal of Bacteriology, volume 171, no. 3, March 1989, American Society for Microbiology, (US), B. Lipinska et al.: "Identification, Characterization, and mapping of the Escherichia coli htrA gene, whose product is essential for bacterial growth only at elevated temperatures", pages 1574-1584 * |
Journal of Bacteriology, volume 171, no. 5, May 1989, American Society for Microbiology, (US), B. Bukau et al.: "Cellular defects caused by deletion of the Escherichia coli dnaK gene indicate roles for heat shock protein in normal metabolism", pages 2337-2346 * |
Journal of Bacteriology, volume 172, no. 2, February 1990, American Society for Microbiology, (US), J.W. Foster et al.: "Adaptive acidification tolerance response of Salmonella typhimurium", pages 771-778 * |
Proc. Natl. Acad. Sci., volume 86, 1989, (US) E.A. Groisman et al.: "Salmonella typhimurium phoP virulence gene is a transcriptional regulator", pages 7077-7081 * |
The EMBO Journal, volume 8, no. 11, 1989, IRL Press, (Oxford, GB)), N. Kusukawa et al.: "Effects of mutations in heat-shock genes groES and groEL on protein export in Escherichia coli", pages 3517-3521 * |
Vaccine, volume 7, no. 6, December 1989, Butterworth & Co., (London, GB), S.N. Chatfield et al.: "Live Salmonella as vaccines and carriers of foreign antigenic determinants", pages 495-498 * |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662908A (en) * | 1985-07-31 | 1997-09-02 | The Board Of Trustees Of The Leland Stanford Jr. University | Invasive microorganisms |
US6482614B1 (en) | 1988-06-15 | 2002-11-19 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US6335183B1 (en) | 1988-06-15 | 2002-01-01 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US7501234B2 (en) | 1989-06-15 | 2009-03-10 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US5547664A (en) * | 1991-03-05 | 1996-08-20 | Burroughs Wellcome Co. | Expression of recombinant proteins in attenuated bacteria |
US5683700A (en) * | 1991-03-05 | 1997-11-04 | Glaxo Wellcome Inc. | Expression of recombinant proteins in attenuated bacteria |
AU675940B2 (en) * | 1992-03-02 | 1997-02-27 | Board Of Trustees Of The Leland Stanford Junior University | Microorganisms having attenuated invasiveness |
US5663317A (en) * | 1992-03-02 | 1997-09-02 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Microorganism having attenuated invasiveness |
US5747309A (en) * | 1992-09-04 | 1998-05-05 | University Of Saskatchewan | Bacterial vaccines using vaccine strains of pathogenic bacteria |
US6017544A (en) * | 1994-01-13 | 2000-01-25 | Mount Sinai School Of Medicine Of The University Of New York | Composition comprising immunogenic stress protein-peptide complexes against cancer and a cytokine |
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US6468540B1 (en) | 1994-01-13 | 2002-10-22 | Mount Sinai School Of Medicine Of New York University | Immunotherapeutic stress protein-peptide complexes against cancer |
US6610659B1 (en) | 1994-01-13 | 2003-08-26 | Mount Sinai School Of Medicine Of New York University | Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease |
US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
WO1995020665A1 (en) * | 1994-01-31 | 1995-08-03 | Medeva Holdings B.V. | Expression of heterologous proteins in attenuated bacteria using the htra-promoters |
KR100392916B1 (en) * | 1994-01-31 | 2003-10-22 | 메데바 홀딩스 비브이 | How to express heterologous proteins in attenuated bacteria using the htrA-promoter |
US5961979A (en) * | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US6455503B1 (en) | 1994-03-16 | 2002-09-24 | Mount Sinai School Of Medicine Of New York University | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US6048530A (en) * | 1994-03-16 | 2000-04-11 | Mount Sinai School Of Medicine Of New York University | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US7601359B1 (en) | 1995-09-13 | 2009-10-13 | Fordham University | Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins |
US6030618A (en) * | 1995-09-13 | 2000-02-29 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US5985270A (en) * | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US6136315A (en) * | 1995-09-13 | 2000-10-24 | Fordham University | Compositions and methods using complexes of heat shock protein 70 and antigenic molecules for the treatment and prevention of neoplastic diseases |
US6139841A (en) * | 1995-09-13 | 2000-10-31 | Fordham University | Compositions and methods using complexes of heat shock protein 70 and antigenic molecules for the treatment and prevention of infectious diseases |
US6143299A (en) * | 1995-09-13 | 2000-11-07 | Fordham University | Compositions and methods using complexes of heat shock protein gp96 and antigenic molecules for the treatment and prevention of infectious diseases |
US6156302A (en) * | 1995-09-13 | 2000-12-05 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US6162436A (en) * | 1995-09-13 | 2000-12-19 | Fordham University | Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases |
US6187312B1 (en) | 1995-09-13 | 2001-02-13 | Fordham University | Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of infectious diseases |
US6461615B1 (en) | 1995-09-13 | 2002-10-08 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5837251A (en) * | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
US6447781B1 (en) | 1995-09-13 | 2002-09-10 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US6410028B1 (en) | 1995-09-13 | 2002-06-25 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US6413830B1 (en) | 1996-03-01 | 2002-07-02 | Sven E. Wahlstrom | Dynamic random access memory |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
US6383491B1 (en) | 1997-02-07 | 2002-05-07 | Fordham University | Prevention of infectious diseases with hsp90-peptide complexes |
US6383493B1 (en) | 1997-02-07 | 2002-05-07 | Fordham University | Methods and compositions for eliciting an immune response with hsp70-peptide complexes |
US6391306B1 (en) | 1997-02-07 | 2002-05-21 | Fordham University | Treatment of infectious diseases with hsp90-peptide complexes |
US6399069B1 (en) | 1997-02-07 | 2002-06-04 | Fordham University | Prevention of infectious diseases with hsp70-peptide complexes |
US6399070B1 (en) | 1997-02-07 | 2002-06-04 | Fordham University | Methods and compositions for eliciting an immune response with hsp90-peptide complexes |
US6403095B1 (en) | 1997-02-07 | 2002-06-11 | Fordham University | Treatment of primary and metastatic neoplastic diseases with HSP70-peptide complexes |
US5830464A (en) * | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6383492B1 (en) | 1997-02-07 | 2002-05-07 | Fordham University | Treatment of infectious diseases with gp96-peptide complexes |
US6017540A (en) * | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
US6387374B1 (en) | 1997-02-07 | 2002-05-14 | Fordham University | Treatment of primary and metastatic neoplastic diseases with hsp90-peptide complexes |
US6383494B1 (en) | 1997-02-07 | 2002-05-07 | Fordham University | Methods and composition for eliciting an immune response with gp96-peptide complexes |
US6436404B1 (en) | 1997-02-07 | 2002-08-20 | Fordham University | Prevention of primary and metastatic neoplastic diseases with GP96-peptide complexes |
US6379672B1 (en) | 1997-02-07 | 2002-04-30 | Fordham University | Prevention of infectious diseases with gp96-peptide complexes |
US6447780B1 (en) | 1997-02-07 | 2002-09-10 | Fordham University | Prevention of primary and metastatic neoplastic diseases with hsp90-peptide complexes |
US6375953B1 (en) | 1997-02-07 | 2002-04-23 | Fordham University | Treatment of infectious diseases with HSP70-peptide complexes |
US6455048B1 (en) | 1997-02-07 | 2002-09-24 | Fordham University | Prevention of primary and metastatic neoplastic diseases with hsp70-peptide complexes |
US6322790B1 (en) | 1997-02-07 | 2001-11-27 | Fordham University | Compositions and methods for eliciting an immune response using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6524825B1 (en) | 1997-08-05 | 2003-02-25 | Stressgen Biotechnologies, Inc. | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
US6900035B2 (en) | 1997-08-05 | 2005-05-31 | Stressgen Biotechnologies, Inc. | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
US7262014B2 (en) | 1997-08-05 | 2007-08-28 | Stressgen Biotechnologies Corporation | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
US5948646A (en) * | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
US6410027B1 (en) | 1997-12-11 | 2002-06-25 | Fordham University | Methods for preparation of vaccines against cancer |
US6406700B1 (en) | 1997-12-11 | 2002-06-18 | Fordham University | Methods for preparation of vaccines against cancer |
US6410026B1 (en) | 1997-12-11 | 2002-06-25 | Fordham University | Methods for preparation of vaccines against cancer |
US8685384B2 (en) | 1998-02-20 | 2014-04-01 | University Of Miami | Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex |
CZ301520B6 (en) * | 1998-03-25 | 2010-03-31 | Peptide Therapeutics Limited | Bacterium attenuated by a non-reverting mutation, vaccine in which the bacterium is comprised and use thereof |
US6902906B1 (en) | 1998-03-25 | 2005-06-07 | Acambis Research Limited | Bacteria attenuated by a non-reverting mutation in each of the aroC, ompF and ompC genes, useful as vaccines |
WO1999049026A1 (en) * | 1998-03-25 | 1999-09-30 | Peptide Therapeutics Limited | Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines |
US6497880B1 (en) | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
FR2787810A1 (en) * | 1998-12-24 | 2000-06-30 | Agronomique Inst Nat Rech | GRAM POSITIVE BACTERIA WITHOUT PROTEASIC ACTIVITY HTRA, AND USES THEREOF |
US6994997B1 (en) | 1998-12-24 | 2006-02-07 | Institut National De La Recherche Agronomique | Gram positive bacteria deprived of HtrA protease activity and their uses |
WO2000039309A1 (en) * | 1998-12-24 | 2000-07-06 | Institut National De La Recherche Agronomique | GRAM-POSITIVE BACTERIA DEPRIVED OF HtrA PROTEASIC ACTIVITY AND THEIR USES |
US6657055B2 (en) | 1999-07-08 | 2003-12-02 | Stressgen Biotechnologies Corporation | Induction of a Th1-like response in vitro |
US6495347B1 (en) | 1999-07-08 | 2002-12-17 | Stressgen Biotechnologies Corporation | Induction of a Th1-like response in vitro |
US6875435B2 (en) | 2000-01-14 | 2005-04-05 | Whitehead Institute For Biomedical Research | In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
US7501125B2 (en) | 2000-01-14 | 2009-03-10 | Whitehead Institute For Biomedical Research | Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
US7449557B2 (en) | 2000-06-02 | 2008-11-11 | University Of Connecticut Health Center | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
US7211411B2 (en) | 2000-06-26 | 2007-05-01 | Nventa Biopharmaceuticals Corporation | Human papilloma virus treatment |
US6797491B2 (en) | 2000-06-26 | 2004-09-28 | Stressgen Biotechnologies Corporation | Human papilloma virus treatment |
US7754449B2 (en) | 2000-06-26 | 2010-07-13 | Nventa Biopharmaceuticals Corporation | Human papilloma virus treatment |
US6921534B2 (en) | 2001-02-05 | 2005-07-26 | Stressgen Biotechnologies Corporation | Hepatitis B virus treatment |
WO2002097081A2 (en) * | 2001-05-30 | 2002-12-05 | Brane Tech S.R.L. | Method to generate non virulent microorganisms from pathogenic ones trough permanent genetic modification of their biological membrane for vaccine production |
WO2002097081A3 (en) * | 2001-05-30 | 2003-09-25 | Brane Tech S R L | Method to generate non virulent microorganisms from pathogenic ones trough permanent genetic modification of their biological membrane for vaccine production |
US7666581B2 (en) | 2001-08-20 | 2010-02-23 | University Of Connecticut Health Center | Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease |
US9238064B2 (en) | 2008-03-03 | 2016-01-19 | University Of Miami | Allogeneic cancer cell-based immunotherapy |
US8475785B2 (en) | 2008-03-03 | 2013-07-02 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
US8968720B2 (en) | 2008-03-20 | 2015-03-03 | University Of Miami | Heat shock protein GP96 vaccination and methods of using same |
WO2013011509A1 (en) * | 2011-07-21 | 2013-01-24 | State Of Israel, Represented By Prime Minister's Office Institute For Biological Research | BACILLUS ANTHRACIS HtrA-DEFECTIVE-DERIVED VACCINES |
US10046047B2 (en) | 2015-02-06 | 2018-08-14 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
US10758611B2 (en) | 2015-02-06 | 2020-09-01 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
US10780161B2 (en) | 2015-02-06 | 2020-09-22 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
Also Published As
Publication number | Publication date |
---|---|
IL97720A0 (en) | 1992-06-21 |
MY130001A (en) | 2007-05-31 |
EP0524205A1 (en) | 1993-01-27 |
IE911037A1 (en) | 1991-10-09 |
AU7541791A (en) | 1991-10-30 |
IL97720A (en) | 1999-06-20 |
DK0524205T3 (en) | 1997-10-27 |
KR100202771B1 (en) | 1999-06-15 |
HU217776B (en) | 2000-04-28 |
AU659995B2 (en) | 1995-06-08 |
JP3054440B2 (en) | 2000-06-19 |
EP0524205B1 (en) | 1997-08-27 |
ATE157397T1 (en) | 1997-09-15 |
JPH05507842A (en) | 1993-11-11 |
GR3025258T3 (en) | 1998-02-27 |
DE69127440D1 (en) | 1997-10-02 |
CA2079463C (en) | 2002-03-05 |
ES2106776T3 (en) | 1997-11-16 |
ZA912397B (en) | 1992-11-25 |
TW205567B (en) | 1993-05-11 |
DE69127440T2 (en) | 1998-01-02 |
HU9203098D0 (en) | 1992-12-28 |
HUT65496A (en) | 1994-06-28 |
US5804194A (en) | 1998-09-08 |
US5980907A (en) | 1999-11-09 |
CA2079463A1 (en) | 1991-10-01 |
NZ237616A (en) | 1994-03-25 |
GB9007194D0 (en) | 1990-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5804194A (en) | Vaccines containing a salmonella bacteria attenuated by mutation of the htra gene | |
EP0400958B1 (en) | Live vaccines | |
CA2013573C (en) | Vaccines containing avirulent phop-type microorganisms | |
EP0574466B1 (en) | Expression of recombinant proteins in attenuated bacteria | |
EP0563311B1 (en) | Improved vaccines | |
EP0322237B1 (en) | Vaccines | |
Chatfield et al. | The development of oral vaccines based on live attenuated Salmonella strains | |
US5811105A (en) | Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway | |
AU659995C (en) | Live vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA HU JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2079463 Country of ref document: CA |
|
COP | Corrected version of pamphlet |
Free format text: PAGE CONCERNING DEPOSIT OF MICROORGANISM ADDED |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991906493 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991906493 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991906493 Country of ref document: EP |